NSCLC cases whose specimen lacked ERCC1 expression had a more prominent response to adjuvant cisplatin treatment and hence ERCC1 expression holds promise as a predictive biomarker. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.